Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 5/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.57 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350928 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL2730825 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL724604 | 0.90 | ACHE (0.69) | BCHEACHEBACE1 | |
| SCHEMBL242760 | 0.90 | ACHE (0.69) | BCHEACHEBACE1 | |
| SCHEMBL242759 | 0.90 | ACHE (0.69) | BCHEACHEBACE1 | |
| Bromide SCHEMBL2497824 | 0.89 | ACHE (0.68) | BCHEACHEBACE1 | |
| SCHEMBL4621350 | 0.88 | ACHE (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27735117 | 0.86 | ACHE (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL16386020 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14252995 | 0.85 | ALDH1A1 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137608-B | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2020-06-19 | — | — | CN | disclosed |
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| CN-108137608-A | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2018-06-08 | — | — | CN | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-8507675-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012058645-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7432370-B2 | Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | CYP1A2 637/4885CYP3A4 1945/4885CYP2D6 1311/4885 |
| US-20120010407-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | CYP1A2 2632/4885CYP3A4 1730/4885CYP2D6 1607/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20120010406-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | CYP1A2 4339/4885CYP3A4 4034/4885CYP2D6 4098/4885 |
| US-20120016131-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
| US-20120046245-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP1A2 2611/4885CYP3A4 3814/4885CYP2D6 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.